Analyst Price Targets — PRLD
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| April 27, 2026 11:33 am | — | H.C. Wainwright | $8.00 | $4.70 | TheFly | Prelude Therapeutics price target raised to $8 from $5 at H.C. Wainwright |
| September 10, 2024 6:43 am | Robert Burns | H.C. Wainwright | $5.00 | $5.17 | StreetInsider | H.C. Wainwright Reiterates Neutral Rating on Prelude Therapeutics (PRLD) |
| June 20, 2024 5:33 am | Peter Lawson | Barclays | $3.00 | $3.87 | TheFly | Prelude Therapeutics downgraded to Underweight from Equal Weight at Barclays |
| March 13, 2024 2:51 am | Reni Benjamin | JMP Securities | $7.00 | $4.62 | StreetInsider | JMP Securities Starts Prelude Therapeutics (PRLD) at Market Outperform, 'Precision Targeting of SMARCA Drives Cell Kill' |
| November 17, 2022 6:12 am | — | H.C. Wainwright | $15.00 | $7.70 | Benzinga | HC Wainwright & Co. Maintains Buy on Prelude Therapeutics, Lowers Price Target to $15 |
| November 15, 2022 8:41 am | — | Morgan Stanley | $10.00 | $8.10 | Benzinga | Morgan Stanley Maintains Equal-Weight on Prelude Therapeutics, Lowers Price Target to $10 |
Latest News for PRLD
The consensus price target hints at a 58.4% upside potential for Prelude Therapeutics (PRLD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
ADAR1 Capital Management LLC purchased a new position in shares of Prelude Therapeutics Incorporated (NASDAQ: PRLD) during the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 152,825 shares of the company's stock, valued at approximately $523,000. ADAR1 Capital Management
Prelude Therapeutics (PRLD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Prelude Therapeutics Incorporated (PRLD) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for PRLD.
U.S. House Trading
No House trades found for PRLD.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.